Miguel Salavert et al <br/><br/>
Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spainq 

<br/><br/><label>Subjects--Topical Terms: </label><br/>Computer science, information & general works